SEC Form 4 · accession 0001140361-18-014120
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A. Lewicki
Officer — President & CEO
Period of report
Mar 16, 2018
Accepted (ET)
Mar 19, 2018 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.98 | Mar 16, 2018 | A | 125,000 | A | — | Mar 15, 2028 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of March 16, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.